Quanterix Names Jim Gauthier Interim CEO at Annualized Salary of $750,000
Key Facts
Quanterix announced on November 18, 2026, that Everett Cunningham had stepped down as president and chief executive officer and as a member of the board, and appointed Jim Gauthier interim president and CEO. The company said Cunningham had accepted another opportunity in the healthcare sector, and Gauthier, who had served as chief commercial officer, took on the role the same day. The decision puts the company’s temporary leadership in the hands of its commercial chief as the board begins its search for a permanent successor. In its filing, Quanterix said Cunningham’s departure was not related to disagreements with the company over its operations, policies or practices. It added that the departure was not connected to financial disclosure, accounting, or any legal matter.
Quanterix said Gauthier will receive an annualized salary of $750,000 for the duration of his service as interim CEO. Gauthier joined the company in August 2026 as chief commercial officer before taking on the two executive roles on an interim basis. He is 52 and worked at Exact Sciences from August 2024 to August 2026, according to the company’s filing. Before that, he spent about two decades at GE HealthCare, according to Quanterix’s announcement. His background combines commercial roles at diagnostics and healthcare companies, as the company said Gauthier would focus on improving commercial execution, accelerating revenue growth and expanding its position in diagnostics.
The board has begun its search for a permanent CEO and hired an executive search firm for that purpose, according to Quanterix’s announcement. The company said it would consider internal and external candidates, without setting a timetable for selecting the new CEO. In the meantime, Cunningham will remain available to help with an orderly transition of his responsibilities through December 11, 2026. The arrangement provides a defined transition period between the departing CEO and Gauthier, who began his interim duties on November 18. The company’s filing did not state when the interim appointment would end or set a timetable for completing the search.
Alongside the leadership change, Quanterix reaffirmed its 2026 financial outlook, which it issued on November 9. The company had set a projected full-year revenue range of $142 million to $146 million, with an adjusted gross margin of 48% to 50%. It also expected to end the year with about $70 million in cash and no debt. The reaffirmation came in the announcement of the CEO change, in which the board said the company had made progress in its Alzheimer’s diagnostics business during 2026 and developed strategies for its research tools business. The announcement did not revise the outlook or link it to Cunningham’s departure.
Quanterix reported revenue of $35 million in the third quarter of 2026, up 6.3% from the second quarter but below $40.233 million in the third quarter of 2025. The company posted a net loss of $21.6 million in the third quarter, which its results described as a 35.6% improvement from the same period a year earlier. It ended the quarter with $80.7 million in cash, cash equivalents, marketable securities and restricted cash. On November 18, the company’s stock, which trades under the ticker QTRX, closed at $2.07, according to EL7 data. The available evidence did not include documented session highs or lows for the stock.
In its latest commercial move before announcing the leadership change, Quanterix said on November 16 that it had reached an exclusive distribution agreement with Sherman Abrams Laboratory to expand access to the Lucent AD Complete blood test for Alzheimer’s detection in New Jersey and the surrounding region. On product development, the company said its high-plex TAME and ADx panels were scheduled to ship in early 2027. The TAME panel offers a broader view of the tumor immune environment, while the ADx panel is among tools for measuring biomarkers associated with therapies. Quanterix said its focus would include improving commercial execution, accelerating revenue growth and expanding its diagnostics business. The search for a permanent CEO and Cunningham’s transition assistance through December 11, 2026, remain the next announced steps in the succession process.